Fourth Pfizer shot gave triple protection from severe COVID-19 in Israel

Embargoed until: Publicly released: 2022-04-06 07:00

International

Israelis aged 60-plus could get a fourth Pfizer BioNTech vaccine from early 2022. In a new study (abstract only) of over 1.2 million older Israelis, people given a fourth dose had a 3.5 times lower rate of severe COVID-19 illness in the fourth week afterwards than people with a triple dose. A fourth vaccine also held up against becoming infected - in the same timeframe, confirmed infection was twice as low compared to three doses. The protection against serious illness from a fourth shot didn’t wane within six weeks, however its defences against infection declined during this timespan.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research NEJM Group, Web page Post-embargo URL

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: Weizmann Institute of Science, Technion–Israel Institute of Technology, the Hebrew University of Jerusalem, Israel Ministry of Health, Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Aviv University (all Israel)

Funder: No funding information available yet.

Media Contact/s

Contact details are only visible to registered journalists.